About Coral Laboratories
Coral Laboratories is a publicly listed company based in Mumbai (India) founded in 1981. Manufacturer of generic drugs. The company has 197 employees. Its Indian entity Coral Laboratories Limited reported revenue of ₹96.11 Cr. Coral Laboratories offers products and services including Tablets and Injections. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Coral Laboratories was founded in 1981 in Mumbai, India, within the pharmaceutical sector. Operations center on the production of generic drugs across multiple therapeutic categories. The portfolio encompasses antibiotics, vitamin and iron supplements, antacids, analgesics, anti-inflammatories, antidiabetics, cardiac medications, and topical preparations such as eye and ear drops. Focus remains on standard formulations for domestic and potential international distribution.
- Headquarters Mumbai, India
- Employees 197
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website corallab.com
- Social LinkedIn
- Legal Name Coral Laboratories Limited
- Market Cap₹189 Cr
CORALAB · BSE
- Share Price₹539.00
+1.86% today
- Revenue₹85.90 Cr
FY 2025-26 · -25.3% YoY
- EBITDA₹15.21 Cr
Margin 17.7%
- Net Profit₹15.98 Cr
FY 2025-26 · -35.4% YoY
- P/E (TTM)10.1x
P/B 0.9x
- ROE8.0%
ROCE 11.1%
- Debt / Equity0.02
Interest cover 1.3x
- Employee Count197
Associated legal entities of Coral Laboratories
Coral Laboratories operates through Coral Laboratories Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Coral Laboratories Limited Listed CIN L24231MH1997PLC422233 | Active | 06 Feb 1997 | Mumbai, Maharashtra | ₹96.1 Cr | 103 | 8 | View details |
Products & Services of Coral Laboratories
Coral Laboratories offers a comprehensive portfolio of products and services, including Tablets and Injections.
Tablets are manufactured for various therapeutic uses, ensuring they meet quality standards for customer satisfaction.
Injections are produced in liquid and powder forms for medical treatments, with emphasis on sterility and international compliance.
Board of directors of Coral Laboratories Limited (Coral Laboratories)
Coral Laboratories Limited is the primary company behind Coral Laboratories. The board of Coral Laboratories Limited currently have 6 directors; the longest-serving is Girish Madanlal Dhameja, appointed in 2017. 14 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Girish Madanlal Dhameja DIN 07798455 | Whole-time director | 26 May 2017 | 9 yrs 5 mo | Coral Laboratories Limited |
| Sushma Shashi Kadkade DIN 07791735 | Director | 26 May 2017 | 9 yrs 5 mo | Coral Laboratories Limited |
| Saurabh Kamlesh Shah DIN 08451204 | Director | 28 May 2019 | 7 yrs 5 mo | Coral Laboratories Limited |
| Malay Sureshkumar Doshi DIN 09186000 | Director | 27 May 2021 | 5 yrs 5 mo | Coral Laboratories Limited |
| Rajendrasinh Ajitsinh Rana DIN 09306136 | Director | 03 Sep 2021 | 5 yrs 2 mo | Coral Laboratories Limited |
| Pooja Sanjiv Hindia DIN 09840237 | Director | 09 Aug 2024 | 2 yrs 3 mo | Coral Laboratories Limited |
IPO & Listings of Coral Laboratories
Coral Laboratories is a publicly listed company on the BSE with ticker symbol CORALAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Dec 2001
- Listed onBSE: 524506
- Listed entityCoral Laboratories Limited
- Exchange sectorHealth technology
- ISININE683E01017
- Share price₹566.15 (+3.96% on the day) · 2026-10-14
- Market capitalisation₹195 Cr
- Price to earnings10.5
- EPS (diluted, trailing year)₹53.76
- Dividend yield0.37%
- Volume (last session)979
Financials of Coral Laboratories
Exchange-reported figures of Coral Laboratories Limited, the listed company behind Coral Laboratories (BSE: CORALAB).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 85.90 | 115 | 83.66 | 78.12 | 75.61 | 96.57 | 70.58 |
| Revenue growth | -25.3% | +37.5% | +7.1% | +3.3% | -21.7% | +36.8% | - |
| EBITDA | 15.21 | 25.46 | 16.07 | 3.81 | 8.21 | 15.86 | 5.42 |
| EBITDA margin | +17.7% | +22.1% | +19.2% | +4.9% | +10.9% | +16.4% | +7.7% |
| Profit before tax | 23.11 | 32.46 | 20.72 | 8.22 | 11.85 | 17.63 | 9.11 |
| Net profit | 15.98 | 24.72 | 15.90 | 6.41 | 8.31 | 13.56 | 7.12 |
| Net profit margin | +18.6% | +21.5% | +19.0% | +8.2% | +11.0% | +14.0% | +10.1% |
| EPS (₹) | 45.85 | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 | 19.96 |
| Balance sheet | |||||||
| Total assets | 214 | 206 | 178 | 160 | 168 | 144 | 122 |
| Net worth | 209 | 201 | 177 | 155 | 156 | 137 | 116 |
| Total debt | 4.33 | 3.56 | 0.00 | 0.00 | 6.04 | 6.25 | 5.91 |
| Cash & bank | 72.54 | 79.87 | 61.28 | 40.41 | 37.48 | 34.83 | 29.99 |
| Net working capital | 125 | 128 | 103 | 87.81 | 89.56 | 88.23 | 76.67 |
| Cash flow | |||||||
| Cash from operations | 15.62 | (1.22) | (5.46) | 12.67 | 6.08 | 0.93 | (3.86) |
| Cash from investing | (17.71) | (0.15) | 1.40 | (2.61) | (6.05) | (0.07) | (1.55) |
| Cash from financing | 0.06 | 2.71 | 0.01 | (6.43) | 0.15 | 0.35 | 3.56 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29.62 | 26.48 | 21.56 | 19.03 | 18.82 | 28.13 | 22.99 | 32.23 |
| Revenue growth (YoY) | +57.4% | -5.9% | -6.2% | -41.0% | -40.6% | - | - | - |
| Other income | 2.15 | 2.65 | 2.49 | 3.03 | 2.05 | 2.48 | 2.52 | 2.54 |
| Total expenses | 24.14 | 20.29 | 19.67 | 14.10 | 16.64 | 26.22 | 16.67 | 25.72 |
| EBITDA | 5.48 | 6.19 | 1.89 | 4.93 | 2.18 | 1.91 | 6.32 | 6.51 |
| EBITDA margin | +18.5% | +23.4% | +8.8% | +25.9% | +11.6% | +6.8% | +27.5% | +20.2% |
| Depreciation | 0.66 | 0.54 | 0.69 | 0.45 | 0.45 | 0.51 | 0.50 | 0.51 |
| Interest | 0.03 | 0.01 | 0.00 | 0.10 | 0.06 | 0.04 | 0.02 | 0.01 |
| Profit before tax | 6.94 | 8.29 | 3.69 | 7.41 | 3.72 | 3.84 | 8.32 | 8.53 |
| Tax | 1.56 | 3.06 | 0.92 | 1.60 | 1.16 | 1.02 | 2.17 | 2.15 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29.62 | 26.48 | 21.56 | 19.03 | 18.82 | 28.13 | 22.99 | 32.23 |
| Revenue growth (YoY) | +57.4% | -5.9% | -6.2% | -41.0% | -40.6% | - | - | - |
| Other income | 2.15 | 2.65 | 2.49 | 3.03 | 2.05 | 2.48 | 2.52 | 2.54 |
| Total expenses | 24.14 | 20.29 | 19.67 | 14.10 | 16.64 | 26.22 | 16.67 | 25.72 |
| EBITDA | 5.48 | 6.19 | 1.89 | 4.93 | 2.18 | 1.91 | 6.32 | 6.51 |
| EBITDA margin | +18.5% | +23.4% | +8.8% | +25.9% | +11.6% | +6.8% | +27.5% | +20.2% |
| Depreciation | 0.66 | 0.54 | 0.69 | 0.45 | 0.45 | 0.51 | 0.50 | 0.51 |
| Interest | 0.03 | 0.01 | 0.00 | 0.10 | 0.06 | 0.04 | 0.02 | 0.01 |
| Profit before tax | 6.94 | 8.29 | 3.69 | 7.41 | 3.72 | 3.84 | 8.32 | 8.53 |
| Tax | 1.56 | 3.06 | 0.92 | 1.60 | 1.16 | 1.02 | 2.17 | 2.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 85.90 | 115 | 83.66 | 78.12 | 75.61 | 96.57 | 70.58 |
| Revenue growth | -25.3% | +37.5% | +7.1% | +3.3% | -21.7% | +36.8% | - |
| Other income | 10.21 | 9.11 | 6.63 | 6.93 | 5.77 | 3.79 | 5.89 |
| Total expenses | 70.69 | 89.55 | 67.59 | 74.31 | 67.40 | 80.71 | 65.16 |
| Employee cost | 15.92 | 14.74 | 11.20 | 11.13 | 11.23 | 10.18 | 9.70 |
| EBITDA | 15.21 | 25.46 | 16.07 | 3.81 | 8.21 | 15.86 | 5.42 |
| EBITDA margin | +17.7% | +22.1% | +19.2% | +4.9% | +10.9% | +16.4% | +7.7% |
| Depreciation | 2.14 | 2.01 | 1.98 | 2.18 | 1.99 | 1.98 | 2.01 |
| Interest | 0.17 | 0.10 | 0.00 | 0.34 | 0.14 | 0.04 | 0.19 |
| Profit before tax | 23.11 | 32.46 | 20.72 | 8.22 | 11.85 | 17.63 | 9.11 |
| Tax | 6.73 | 8.31 | 4.94 | 1.78 | 2.81 | 4.06 | 1.99 |
| Net profit | 15.98 | 24.72 | 15.90 | 6.41 | 8.31 | 13.56 | 7.12 |
| Net profit margin | +18.6% | +21.5% | +19.0% | +8.2% | +11.0% | +14.0% | +10.1% |
| EPS (₹) | 45.85 | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 | 19.96 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 3.57 | 3.57 | 3.57 | 3.57 | 3.57 | 3.57 | 3.57 |
| Reserves & surplus | 206 | 198 | 174 | 151 | 152 | 133 | 112 |
| Shareholders' funds (net worth) | 209 | 201 | 177 | 155 | 156 | 137 | 116 |
| Secured loans | 4.33 | 3.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 6.04 | 6.25 | 5.91 |
| Total debt | 4.33 | 3.56 | 0.00 | 0.00 | 6.04 | 6.25 | 5.91 |
| Total liabilities | 214 | 206 | 178 | 160 | 168 | 144 | 122 |
| Assets | |||||||
| Gross block | 71.61 | 51.45 | 51.43 | 50.66 | 47.07 | 42.74 | 41.80 |
| Net block | 44.13 | 22.73 | 24.28 | 25.27 | 23.78 | 21.44 | 22.56 |
| Capital work in progress | 0.04 | 2.48 | 0.00 | 0.00 | 1.72 | 0.50 | 0.00 |
| Investments | 46.11 | 52.34 | 49.75 | 41.29 | 46.18 | 33.18 | 24.87 |
| Inventories | 20.53 | 9.87 | 15.16 | 12.50 | 18.36 | 21.67 | 19.30 |
| Sundry debtors | 29.43 | 33.64 | 28.19 | 23.42 | 38.11 | 39.16 | 34.41 |
| Cash & bank balances | 72.54 | 79.87 | 61.28 | 40.41 | 37.48 | 34.83 | 29.99 |
| Loans & advances | 25.14 | 25.62 | 23.51 | 23.33 | 15.09 | 13.88 | 12.14 |
| Total current assets | 148 | 149 | 128 | 99.66 | 109 | 110 | 95.84 |
| Total current liabilities | 22.98 | 21.40 | 24.90 | 11.85 | 19.48 | 21.31 | 19.17 |
| Net working capital | 125 | 128 | 103 | 87.81 | 89.56 | 88.23 | 76.67 |
| Total assets | 214 | 206 | 178 | 160 | 168 | 144 | 122 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.41 | 2.07 | 6.13 | 2.51 | 2.32 | 1.11 | 2.97 |
| Net cash from operating activities | 15.62 | (1.22) | (5.46) | 12.67 | 6.08 | 0.93 | (3.86) |
| Net cash from investing activities | (17.71) | (0.15) | 1.40 | (2.61) | (6.05) | (0.07) | (1.55) |
| Net cash from financing activities | 0.06 | 2.71 | 0.01 | (6.43) | 0.15 | 0.35 | 3.56 |
| Net change in cash | (2.03) | 1.33 | (4.06) | 3.62 | 0.18 | 1.21 | (1.86) |
| Closing cash | 72.54 | 79.87 | 61.28 | 40.41 | 37.48 | 34.83 | 29.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -25.3% | +37.5% | +7.1% | +3.3% | -21.7% | +36.8% | - |
| EBITDA growth | -40.3% | +58.4% | +321.8% | -53.6% | -48.2% | +192.6% | - |
| PBT growth | -28.8% | +56.7% | +152.1% | -30.6% | -32.8% | +93.5% | -41.3% |
| Net income growth | -35.4% | +55.5% | +148.1% | -22.9% | -38.7% | +90.5% | - |
| Revenue CAGR (3Y) | +3.2% | +15.0% | -4.7% | +3.4% | -6.0% | +1.5% | -9.6% |
| EBITDA CAGR (3Y) | +58.6% | +45.8% | +0.4% | -11.1% | -12.9% | +1.1% | -38.2% |
| Profitability & leverage | |||||||
| Net income margin | +19.1% | +21.0% | +18.9% | +8.2% | +12.0% | +14.1% | +10.1% |
| Return on capital employed | +11.1% | +17.0% | +12.3% | +5.2% | +7.7% | +13.3% | +7.8% |
| Return on net worth | +8.0% | +12.8% | +9.5% | +4.2% | +6.2% | +10.7% | +6.2% |
| Debt / equity | 0.02 | 0.01 | 0.00 | 0.02 | 0.04 | 0.05 | 0.03 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1.30 | 0.43 | 0.00 | 20.86 | 2.25 | 0.29 | 5.57 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.40 | 2.24 | 1.64 | 1.60 | 1.68 | 2.28 | 1.71 |
| Inventory turnover | 5.65 | 9.19 | 6.05 | 5.06 | 3.78 | 4.71 | 3.98 |
| Debtors turnover | 2.72 | 3.72 | 3.24 | 2.54 | 1.96 | 2.63 | 2.18 |
| EPS (₹) | 45.85 | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 | 19.96 |
| Dividend per share (₹) | 2.00 | 1.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 585.33 | 563.19 | 496.83 | 433.29 | 436.81 | 382.48 | 323.77 |
Web traffic of Coral Laboratories
The website of Coral Laboratories (corallab.com) receives about 1.5K visits a month and ranks #10,768,160 among all websites worldwide, #7,979 in Biotechnology and Pharmaceuticals.
- Monthly visits1.5K
▲ 24.8% vs previous month
- Global rank#10,768,160
among all websites
- Category rank#7,979
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit2.4
- Average visit1 min 00 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Coral Laboratories. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| galpha.com | 100% | 7K | #5,128,365 | View details | |
neongroup.com | neongroup.com | 85% | #12,716,332 | – | |
| megafine.in | 84% | View details | |||
| akorn.com | 84% | #11,843,991 | View details | ||
eolabs.com | eolabs.com | 55% | #2,386,919 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Coral Laboratories
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Coral Laboratories (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Coral Laboratories
Complete news archive for Coral Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Coral Laboratories
Coral Laboratories was founded in 1981.
Coral Laboratories is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Coral Laboratories has 197 employees.
The primary company behind Coral Laboratories, Coral Laboratories Limited, reported revenue of ₹96.11 Cr for FY 2026, down 25% year on year.
Coral Laboratories was founded in 1981 in Mumbai, India, within the pharmaceutical sector. Operations center on the production of generic drugs across multiple therapeutic categories. The portfolio encompasses antibiotics, vitamin and iron supplements, antacids, analgesics, anti-inflammatories, antidiabetics, cardiac medications, and topical preparations such as eye and ear drops. Focus remains on standard formulations for domestic and potential international distribution.
Coral Laboratories offers Tablets and Injections.
Yes, Coral Laboratories is publicly traded on BSE under the ticker symbol CORALAB.
Coral Laboratories operates through Coral Laboratories Limited.
The legal entities of Coral Laboratories currently have 7 directors, including Saurabh Kamlesh Shah, Girish Madanlal Dhameja, Sushma Shashi Kadkade and others.